Found 217 with Last Name = 'marr' and Initial = 'hb' 
Affinity DataIC50: 4.40E+3nMAssay Description:Inhibition of CYP2C9 in human liver microsomeMore data for this Ligand-Target Pair
Affinity DataIC50: 5.10E+3nMAssay Description:Inhibition of CYP3A4 in human liver microsomeMore data for this Ligand-Target Pair
Affinity DataIC50: 1.10E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomeMore data for this Ligand-Target Pair
Affinity DataIC50: 2.10E+4nMAssay Description:Inhibition of CYP1A2 in human liver microsomeMore data for this Ligand-Target Pair
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibition of CYP3A4 in human liver microsomeMore data for this Ligand-Target Pair
3D Structure (crystal)Affinity DataIC50: >3.30E+4nMAssay Description:Inhibition of CYP2C19 in human liver microsomeMore data for this Ligand-Target Pair
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibition of CYP2D6 in human liver microsomeMore data for this Ligand-Target Pair
Affinity DataEC50: 59nMpH: 7.5 T: 2°CAssay Description:The assay measures ligand-mediated interaction of the SRC-1 peptide with the FXR ligand binding domain, using biotinylated FXR LBD coupled to allophy...More data for this Ligand-Target Pair
Affinity DataEC50: 87nMpH: 7.5 T: 2°CAssay Description:The assay measures ligand-mediated interaction of the SRC-1 peptide with the FXR ligand binding domain, using biotinylated FXR LBD coupled to allophy...More data for this Ligand-Target Pair
Affinity DataEC50: 100nMpH: 7.5 T: 2°CAssay Description:The assay measures ligand-mediated interaction of the SRC-1 peptide with the FXR ligand binding domain, using biotinylated FXR LBD coupled to allophy...More data for this Ligand-Target Pair
Affinity DataEC50: 420nMpH: 7.5 T: 2°CAssay Description:The assay measures ligand-mediated interaction of the SRC-1 peptide with the FXR ligand binding domain, using biotinylated FXR LBD coupled to allophy...More data for this Ligand-Target Pair
Affinity DataEC50: 2.30E+3nMpH: 7.5 T: 2°CAssay Description:The assay measures ligand-mediated interaction of the SRC-1 peptide with the FXR ligand binding domain, using biotinylated FXR LBD coupled to allophy...More data for this Ligand-Target Pair
Affinity DataEC50: 65nMAssay Description:The cell-based assay measures the ligand-mediated luminescense resulting from FXR-induced transcription of a luciferase reporter. FXR and the lucifer...More data for this Ligand-Target Pair
Affinity DataEC50: 68nMAssay Description:The cell-based assay measures the ligand-mediated luminescense resulting from FXR-induced transcription of a luciferase reporter. FXR and the lucifer...More data for this Ligand-Target Pair
Affinity DataEC50: 45nMAssay Description:The cell-based assay measures the ligand-mediated luminescense resulting from FXR-induced transcription of a luciferase reporter. FXR and the lucifer...More data for this Ligand-Target Pair
Affinity DataEC50: 500nMAssay Description:The cell-based assay measures the ligand-mediated luminescense resulting from FXR-induced transcription of a luciferase reporter. FXR and the lucifer...More data for this Ligand-Target Pair
Affinity DataEC50: 3.30E+3nMAssay Description:The cell-based assay measures the ligand-mediated luminescense resulting from FXR-induced transcription of a luciferase reporter. FXR and the lucifer...More data for this Ligand-Target Pair
Affinity DataEC50: 105nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 190nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 2.20E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 560nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 410nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 2.00E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 930nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 960nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 930nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 130nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 58nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 110nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 87nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 1.10E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 1.10E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 1.00E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 620nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 480nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 2.20E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 74nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 17nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 48nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 450nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 310nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 460nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 150nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 28nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 51nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 400nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 72nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 78nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 1.10E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
Affinity DataEC50: 7.80E+3nMAssay Description:Agonist activity at human FXR assessed as SRC1 peptide interaction with receptor ligand binding domain by FRET assayMore data for this Ligand-Target Pair
